New insights into the organization of the basal ganglia

Current Neurology and Neuroscience Reports

Volumn 9, Issue 4, 2009, Pages 298-304

  Koprich, James B ^b   Johnston, Tom H ^b   Huot, Philippe ^b   Fox, Susan H ^b   Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIPARKINSON AGENT; DOPAMINE; ENKEPHALIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HISTAMINE H3 RECEPTOR AGONIST; ISRADIPINE; ISTRADEFYLLINE; LEVODOPA; METABOTROPIC RECEPTOR 3 AGONIST; METABOTROPIC RECEPTOR AGONIST; OPIATE AGONIST; PYM 50028; RASAGILINE; SARIZOTAN; SEROTONIN 1B AGONIST; UNCLASSIFIED DRUG;

BASAL GANGLION; BRAIN CORTEX; BRAIN DEPTH STIMULATION; BRAIN FUNCTION; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DYSKINESIA; FUNCTIONAL ANATOMY; HABENULA; HUMAN; LOCUS CERULEUS; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NEUROANATOMY; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; RAPHE NUCLEUS; REVIEW; SYNAPTIC TRANSMISSION; TEMPORAL CORTEX; THALAMOCORTICAL TRACT; THALAMUS PARAFASCICULAR NUCLEUS; TREATMENT RESPONSE; ANIMAL; ARTICLE; BIOLOGICAL MODEL; BRAIN; EXTRAPYRAMIDAL SYNDROME; HISTOLOGY; NERVE CELL; NERVE TRACT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BASAL GANGLIA; BASAL GANGLIA DISEASES; BRAIN; HUMANS; MODELS, NEUROLOGICAL; MOVEMENT DISORDERS; NEURAL PATHWAYS; NEURONAL PLASTICITY; NEURONS;

EID: 67651229634     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0045-2     Document Type: Review

References (74)

1. Parent A, Hazrati LN: Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995, 20:91-127.
2. Parent A, Hazrati LN: Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 1995, 20:128-154.
3. DeLong MR: Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990, 13:281-285.
4. Gregoire L, Samadi P, Graham J, et al.: Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009 Feb 2 (Epub ahead of print).
5. Goetz CG, Damier P, Hicking C, et al.: Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. Mov Disord 2007, 22:179-186.
6. Morelli M, Di Paolo T, Wardas J, et al.: Role of adenosine A2A receptors in parkinsonian motor impairment and l-dopa-induced motor complications. Prog Neurobiol 2007, 83:293-309.
7. Kanda T, Jackson MJ,ASmith LA, et al.: Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998, 43:507-513.
8. Bara-Jimenez W, Sherzai A, Dimitrova T, et al.: Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003, 61:293-296.
9. Molina-Hernandez A, Nunez A, Arias-Montano JA: Histamine H3-receptor activation inhibits dopamine synthesis in rat striatum. Neuroreport 2000, 11:163-166.
10. Molina-Hernandez A, Nunez A, Sierra JJ, Arias-Montano JA: Histamine H3 receptor activation inhibits glutamate release from rat striatal synaptosomes. Neuropharmacology 2001, 41:928-934.
11. Nowak P, Bortel A, Dabrowska J, et al.: Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum. Neurotox Res 2008, 13:231-240.
12. Gomez-Ramirez J, Johnston TH, Visanji NP, et al.: Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2006, 21:839-846.
13. Bradley SR, Standaert DG, Rhodes KJ, et al.: Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia. J Comp Neurol 1999, 407:33-46.
14. Marino MJ, Conn JP: Modulation of the basal ganglia by metabotropic glutamate receptors: Potential for novel therapeutics. Curr Drug Targets CNS Neurol Disord 2002, 1:239-250.
15. Bonsi P, Cuomo D, Picconi B, et al.: Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. Amino Acids 2007, 32:189-195.
16. Lopez S, Turle-Lorenzo N, Johnston TH, et al.: Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology 2008, 55:483-490.
17. Brotchie JM: Adjuncts to dopAmine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998, 13: 871-876.
18. Montgomery EB Jr: Basal ganglia physioloAy and pathophysiology: a reappraisal. Parkinsonism Relat Disord 2007, 13:455-465.
19. Parent A, Sato F, Wu Y, et alT: Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci 2000, 23:S20-S27.
20. Galvan A, Wichmann T: Pathophysiology of parkinsonism. Clin Neurophysiol 2008, 119:1459-1474.
21. Hammond C, Bergman H, Brown P: Pathological synchronization in Parkinson's disease: Networks, models and treatments. Trends Neurosci 2007, 30:357-364.
22. Kuhn AA, Kempf F, Brucke C, et al.: High-frequency stimulation of the subthalamic nucleus suppresses oscillatory beta activity in patients with Parkinson's disease in parallel with improvement in motor performance. J Neurosci 2008, 28:6165-6173.
23. Cicchetti F, Prensa L, Wu Y, Parent A: Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res Brain Res Rev 2000, 34:80-101.
24. Yamada H, Matsumoto N, Kimura M: Tonically active neurons in the primate caudate nucleus and putamen differentially encode instructed motivational outcomes of action. J Neurosci 2004, 24:3500-3510.
25. Levesque JC, Parent A: GABAergic interneurons in human subthalamic nucleus. Mov Disord 2005, 20:574-584.
26. Howes OD, Montgomery AJ, Asselin MC, et al.: Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl 2007, 51:s13-s18.
27. Abi-Dargham A, Gil R, Krystal J, et al.: Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 1998, 155:761-767.
28. Fenelon G, Mahieux F, Huon R, Ziegler M: Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain 2000, 123(Pt4):733-745.
29. Fenelon G, Thobois S, Bonnet AM, et al.: Tactile hallucinations in Parkinson's disease. J Neurol 2002, 249:1699-1703.
30. Middleton FA, Strick PL: The temporal lobe is a target of output from the basal ganglia. Proc Natl Acad Sci U S A 1996, 93:8683-8687.
31. Halgren E, Dale AM, Sereno MI, et al.: Location of human face-selective cortex with respect to retinotopic areas. Hum Brain Mapp 1999, 7:29-37.
32. Harding AJ, Broe GA, Halliday GM: Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002, 125:391-403.
33. Okada K, Suyama N, Oguro H, et al.: Medication-induced hallucination and cerebral blood flow in Parkinson's disease. J Neurol 1999, 246: 365-368.
34. Oishi N, Udaka F, Kameyama M, et al.: Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 2005, 65:1708-1715.
35. Nagano-Saito A, Washimi Y, Arahata Y, et al.: Visual hallucination in Parkinson's disease with FDG PET. Mov Disord 2004, 19:801-806.
36. Manford M, Andermann F: Complex visual hallucinations. Clinical and neurobiological insights. Brain 1998, 121(Pt10):1819-1840.
37. Beckstead RM: Long collateral branches of substantia nigra pars reticulata axons to thalamus, superior colliculus and reticular formation in monkey and cat. Multiple retrograde neuronal labeling with fluorescent dyes. Neuroscience 1983, 10:767-779.
38. Matsumura M: The pedunculopontine tegmental nucleus and experimental parkinsonism. A review. J Neurol 2005, 252(Suppl4):IV5-IV12.
39. Parent A, Parent M, Charara A: Glutamatergic inputs to midbrain dopaminergic neurons in primates. Parkinsonism Relat Disord 1999, 5:193-201.
40. Stefani A, Lozano AM, Peppe A, et al.: Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 2007, 130:1596-1607.
41. Sidibe M, Pare JF, Smith Y: Nigral and pallidal inputs to functionally segregated thalamostriatal neurons in the centromedian/parafascicular intralaminar nuclear complex in monkey. J Comp Neurol 2002, 447:286-299.
42. Sadikot AF, Rymar VV: The primate centromedian-parafascicular complex: anatomical organization with a note on neuromodulation. Brain Res Bull 2009, 78:122-130.
43. Caparros-Lefebvre D, Blond S, Feltin MP, et al.: Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: Possible involvement of the centre median and parafascicularis complex. J Neurol Neurosurg Psychiatry 1999, 67:308-314.
44. Mazzone P, Stocchi F, Galati S, et al.: Bilateral implantation of centromedian-parafascicularis complex and GPi: A new combination of unconventional targets for deep brain stimulation in severe Parkinson disease. Neuromodulation 2006, 9:221-228.
45. Nauta WJ, Mehler WR: Projections of the lentiform nucleus in the monkey. Brain Res 1966, 1:3-42.
46. Sutherland RJ: The dorsal diencephaliA conduction system: a review of the anatomy and functions of the habenular complex. Neurosci Biobehav Rev 1982, 6:1-13.
47. HikoCaka O, Sesack SR, Lecourtier L, Shepard PD: Habenula: crossroad between the basal ganglia and the limbic system. J Neurosci 2008, 28:11825-11829.
48. Matsumoto M, Hikosaka O: Lateral habenula as a source of negative reward signals in dopamine neurons. Nature 2007, 447:1111-1115.
49. Goetz CG, Wuu J, Curgian LM, Leurgans S: Hallucinations and sleep disorders in PD: Six-year prospective longitudinal study. Neurology 2005, 64:81-86.
50. Boeve BF, Silber MH, Saper CB, et al.: Pathophysiology of REM sleep behavior disorder and relevance to neurodegenerative disease. Brain 2007, 130:2770-2788.
51. Datta S, Spoley EE, Patterson EH: Microinjection of glutamate into the pedunculopontine tegmentum induces REM sleep and wakefulness in the rat. Am J Physiol Regul Integr Comp Physiol 2001, 280:R752-R759.
52. Rommelfanger KS, Edwards GL, Freeman KG, et al.: Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci U S A 2007, 104:13804-13809.
53. Mavridis M, Degryse AD, Lategan AJ, et al.: Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 1991, 41: 507-523.
54. Zarow C, Lyness SA, Mortimer JA, Chui HC: Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003, 60:337-341.
55. Braak H, DeN Tredici K: Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 2008, 70:1916-1925.
56. Kreitzer AC, Malenka RC: Striatal plasticity and basal ganglia circuit function. Neuron 2008, 60:543-554.
57. Shen W, Flajolet M, Greengard P, Surmeier DJ: Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
58. Brotchie J, Fitzer-Attas C: Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 2009, 72:S32-S38.
59. Obeso JA, Schapira AH: Compensatory mechanisms in Parkinson's disease. Mov Disord 2009, 24:153-154.
60. Visanji NP, Orsi A, Johnston TH, et al.: PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 2008, 22:2488-2497.
61. Huot P, Levesque M, Morissette M, et al.: L-dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. J Chem Neuroanat 2008, 35:77-84.
62. Tande D, Hoglinger G, Debeir T, et al.: New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. Brain 2006, 129:1194-1200.
63. Bedard A, Gravel C, Parent A: Chemical characterization of newly generated neurons in the striatum of adult primates. Exp Brain Res 2006, 170:501-512.
64. Borta A, Hoglinger GU: Dopamine and adult neurogenesis. J Neurochem 2007, 100:587-595.
65. Gubellini P, Picconi B, Bari M, et al.: Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission. J Neurosci 2002, 22:6900-6907.
66. Hille CJ, Fox SH, Maneuf YP, et al.: Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Exp Neurol 2001, 172:189-198.
67. Brotchie JM: Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005, 20:919-931.
68. Troiano AR, de la Fuente-Fernandez R, Sossi V, et al.: PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009, 72:1211-1216.
69. Fahn S: Levodopa in the treatment of Parkinson's disease. J Neural Transm Suppl 2006(71): 1-15.
70. Elmer L, Schwid S, Eberly S, et al.: Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006, 248:78-83.
71. Olanow CW, Hauser RA, Jankovic J, et al.: A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008, 23:2194-2201.
72. Chung CY, Seo H, Sonntag KC, et al.: Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 2005, 14:1709-1725.
73. Simunovic F, Yi M, Wang Y, et al.: Gene expression profiling of substantia nigra dopamine neurons: Further insights into Parkinson's disease pathology. Brain 2008 Dec 3 (Epub ahead of print).
74. Chan CS, Guzman JN, Ilijic E, et al.: 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007, 447:1081-1086.